HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Use of rHu GM-CSF (Leucomax) in treatment of neutropenia during intensive chemotherapy for acute lymphoblastic leukemia].

Abstract
15 children with ALL and chemotherapy related neutropenia were treated with GM-CSF (Leucomax-Sandoz/Schering-Plough) in a dose of 5 micrograms/kg b.w./day during 7-10 days. Altogether 21 cycles were performed. Increase in the number of neutrophils in the majority of cases was observed already after 3 days of GM-CSF administration. The median time of neutropenia recovery was shorter in children treated with GM-CSF than in the control group. The frequency of severe infections was also significantly lower. No serous side effects were observed.
AuthorsR Rokicka-Milewska, D Derulska, K Pawelec
JournalActa haematologica Polonica (Acta Haematol Pol) Vol. 25 Issue 2 Pg. 111-8 ( 1994) ISSN: 0001-5814 [Print] Poland
Vernacular TitleZastosowanie rHu GM-CSF (Leucomax) w leczeniu neutropenii w przebiegu intensywnej chemioterapii ostrej biaƂaczki limfoblastycznej (obl).
PMID8067182 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use)
  • Humans
  • Male
  • Neutropenia (drug therapy, etiology)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications, drug therapy)
  • Recombinant Proteins (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: